| PEP-0002 | ACE-031 Soluble activin type IIB receptor fusion protein studied for lean mass and metabolic health. One Phase I RCT showed increased lean mass in postmenopausal women; remaining evidence is preclinical. Flagged status, elevated risk. | Score: 5.0 | Elevated | Research chemical |
| PEP-0004 | ADIPONECTIN Endogenous adipose-derived hormone that regulates energy homeostasis and has anti-inflammatory properties. Studied as a biomarker and drug target for metabolic and cognitive conditions; preliminary evidence grade for administered use. | Score: 3.0 | Moderate | Investigational |
| PEP-0005 | ADIPOTIDE Peptidomimetic designed to target and apoptose white adipose tissue vasculature. Studied for metabolic health; preliminary evidence from obese primate models only — no human trials published. Flagged, elevated risk. | Score: 3.0 | Elevated | Research chemical |
| PEP-0008 | ALBIGLUTIDE FDA-approved GLP-1 receptor agonist for type 2 diabetes management. Strong evidence grade — the Harmony Outcomes RCT demonstrated cardiovascular benefit. Approved status, low risk. | Score: 8.4 | Low | FDA-approved |
| PEP-0009 | AOD-9604 Synthetic HGH fragment studied for metabolic health and tissue recovery. Preliminary evidence — no published clinical trial data available in indexed literature. | Score: 2.5 | Moderate | Investigational |
| PEP-0012 | B7-33 Single-chain relaxin-3/RXFP1 peptide agonist studied for metabolic and cardiorenal conditions. Preliminary evidence — early investigational stage with preclinical data. | Score: 2.8 | Moderate | Investigational |
| PEP-0015 | CAGRILINTIDE Long-acting amylin analogue in late-clinical trials for metabolic health and weight management. Strong evidence grade from Phase 2/3 data; most studied in combination with semaglutide (cagrisema). Moderate risk. | Score: 8.4 | Moderate | Investigational |
| PEP-0016 | CAGRISEMA Fixed-dose combination of cagrilintide (amylin analogue) and semaglutide (GLP-1 RA) in late-clinical trials for obesity and metabolic health. Strong evidence from Phase 3 trials showing substantial weight reduction. Low risk. | Score: 8.1 | Low | Investigational |
| PEP-0030 | DULAGLUTIDE DULAGLUTIDE is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 9.4 | Low | FDA-approved |
| PEP-0032 | EXENATIDE EXENATIDE is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health, Longevity & repair, Cognition & mood. | Score: 9.4 | Low | FDA-approved |
| PEP-0037 | GHRELIN GHRELIN is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 5.0 | Moderate | Investigational |
| PEP-0040 | GLP-1 GLP-1 is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 9.0 | Moderate | Investigational |
| PEP-0042 | HCG HCG is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 8.0 | Low | FDA-approved |
| PEP-0044 | HGH FRAGMENT 176-191 HGH FRAGMENT 176-191 is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 2.8 | Moderate | Investigational |
| PEP-0045 | HMG HMG is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 8.6 | Low | FDA-approved |
| PEP-0047 | HUMANIN HUMANIN is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health, Longevity & repair, Cognition & mood. | Score: 3.2 | Elevated | Investigational |
| PEP-0048 | IpamorelinNNC 26-0161 Selective GHS-R agonist (ghrelin mimetic) that elicits a clean GH pulse without significant cortisol or prolactin rise. | Score: 4.0 | Moderate | Investigational |
| PEP-0053 | LINACLOTIDE LINACLOTIDE is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 9.2 | Low | FDA-approved |
| PEP-0054 | LIRAGLUTIDE LIRAGLUTIDE is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 9.8 | Low | FDA-approved |
| PEP-0057 | Melanotan 2 Melanotan 2 is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 3.5 | Elevated | Research chemical |
| PEP-0058 | MODIFIED GRF 1-29 MODIFIED GRF 1-29 is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 5.0 | Moderate | Investigational |
| PEP-0059 | MOTS-C MOTS-C is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 3.5 | Moderate | Investigational |
| PEP-0061 | PASIREOTIDE PASIREOTIDE is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 9.0 | Low | FDA-approved |
| PEP-0063 | PLECANATIDE PLECANATIDE is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 8.8 | Low | FDA-approved |
| PEP-0064 | PRAMLINTIDE PRAMLINTIDE is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 7.8 | Low | FDA-approved |
| PEP-0067 | RetatrutideLY3437943 Triple GIP/GLP-1/glucagon receptor agonist. Phase II data shows substantial weight reduction. Under investigation for metabolic disease. | Score: 7.4 | Low | Investigational |
| PEP-0070 | SEMAGLUTIDEOzempic Long-acting GLP-1 receptor agonist with extensive Phase III and post-marketing data for type-2 diabetes and obesity. | Score: 9.8 | Low | FDA-approved |
| PEP-0073 | SS-31 SS-31 is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health, Tissue recovery. | Score: 5.0 | Moderate | Investigational |
| PEP-0075 | TEDUGLUTIDE TEDUGLUTIDE is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 9.2 | Low | FDA-approved |
| PEP-0076 | TESAMORELIN TESAMORELIN is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 8.6 | Low | FDA-approved |
| PEP-0078 | THYMOSIN ALPHA-1 THYMOSIN ALPHA-1 is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health. | Score: 7.4 | Moderate | Investigational |
| PEP-0079 | TIRZEPATIDE TIRZEPATIDE is catalogued in the Peptides Pub research index, with coverage focused on Metabolic health, Cognition & mood. | Score: 9.6 | Low | FDA-approved |